Another big change that plays into this trend is the switch in markets. Traditionally biotech was B2B focused (eg drugs, ingredients, biofuel commodity plays) but as the science platforms are being developed as articulated in this article we are seeing the beginnings of B2C biotech companies, eg Impossible Foods. I think this shift in the market is also going to drive very different fundraising strategies.